Ownership history in UBS Group AG · 15 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in INNATE PHARMA S A (IPHA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 947 | -3,850 | -80.3% | 0.00% | $2K | $1.75 |
| 2025 Q3 | REDUCED | 4,797 | -1,160 | -19.5% | 0.00% | $9K | $1.93 |
| 2025 Q2 | REDUCED | 5,957 | -3,044 | -33.8% | 0.00% | $11K | $1.82 |
| 2025 Q1 | ADDED | 9,001 | +5,491 | +156.4% | 0.00% | $16K | $1.78 |
| 2024 Q4 | REDUCED | 3,510 | -4,898 | -58.3% | 0.00% | $6K | $1.84 |
| 2024 Q3 | ADDED | 8,408 | +8,111 | +2731.0% | 0.00% | $19K | $2.29 |
| 2024 Q2 | ADDED | 297 | +87 | +41.4% | 0.00% | $576 | $1.94 |
| 2024 Q1 | ADDED | 210 | +64 | +43.8% | 0.00% | $604 | $2.88 |
| 2023 Q4 | UNCHANGED | 146 | — | 0% | 0.00% | $409 | $2.80 |
| 2023 Q3 | UNCHANGED | 146 | — | 0% | 0.00% | $369 | $2.53 |
As of 2025 Q4 — sorted by position size